Delayed-Onset Filler Nodules: How to Tell What They Are
A tender, red swelling at an old filler site, weeks or months after an uneventful treatment, can be a late inflammatory reaction, a low-grade biofilm infection or an acute bacterial infection. They can look alike at first presentation and need different responses [2].
So the first job is sorting, not treating. Ask what has happened to the patient systemically in recent weeks, find out what product is under the skin, and decide whether infection is likely before choosing between antibiotics, steroids and hyaluronidase [2][4]. The patient is often not yours, and a record of what was injected may not exist.
Late nodules behave differently from early ones
Early nodules are usually mechanical: product placed too superficially, or too much of it in one plane. You can feel them on the day and often deal with them on the day.
Late inflammatory reactions typically present as tender, erythematous swelling at or around previous injection sites. They are sometimes bilateral and sometimes involve product that has been in place for a year [1]. Swelling that appears at once at several sites treated on different occasions points to the patient's immune state, not to your technique on any one day.
The interval misleads. A patient who has been well for eight months rarely links a new swelling to a treatment they have stopped thinking about, so the history starts with the swelling. Ask about past treatments directly, and remember that the older the treatment, the less reliable the account.
The trigger is usually a systemic event
The reported triggers are ordinary: flu-like illness and gastrointestinal upset [1][2], and vaccination [3]. What they share is a systemic immune event, not anything local to the face.
A series of cases after COVID-19 vaccination drew particular attention. The authors proposed a mechanism involving angiotensin-converting enzyme pathways to explain both the reaction and the response they saw to treatment [3]. That is a hypothesis fitted to a small number of case reports, not an established mechanism. The useful part is the question it prompts: what has happened to this patient in the past two weeks?
Infection changes the order of treatment
Hyaluronidase feels like the obvious move when the swelling sits at a filler site. Where infection or biofilm is suspected, the consensus algorithm starts systemic antibiotics first and adds hyaluronidase 24 to 48 hours later, when it helps break down the biofilm; an abscess is treated with antibiotics, incision and drainage, and cultured [2].
Consensus guidance on complication management treats this as a sequence, with characterising the lesion placed before intervening on it [2]. Once the enzyme has been given, the picture you needed for the diagnosis is gone. So is any record of how the lesion looked before treatment, which matters to the patient's next clinician and, if the case is disputed, to you.
An unknown product changes the assessment
The person in front of you may have been treated elsewhere, months ago, by someone they no longer want to contact. They may not know what was used, or whether it was hyaluronic acid at all. A permanent or semi-permanent product changes the whole assessment, and a patient's memory of having had filler proves nothing.
If the product might not be hyaluronic acid, the reversibility you are counting on may not exist. Where the product cannot be established, telling the patient so and referring on is a clinical decision, not an admission of inadequacy. An expert consensus recommends recording the product name, amount and batch number in the chart, so that adverse effects can be traced [4].
The evidence comes from case reports
Almost everything in this area rests on case reports, case series and consensus opinion. Reported incidence comes from cohorts assembled in different ways, with different definitions and follow-up periods. Published rates therefore range from 0.02% to 4%, more than a hundredfold, and none should be quoted to a patient as a risk [1][5].
Delayed nodules have been described across manufacturers and cross-linking technologies [1]. A well-documented series with one specific filler does not show that the product caused them rather than simply being the one studied [5].
First steps when a late nodule presents
- Ask about the past few weeks first. Recent illness, dental treatment, vaccination and any new systemic symptom. Ask before you examine, so the answer is not shaped by what you have already found.
- Establish the product. If it is unknown or possibly not hyaluronic acid, slow down rather than trying the enzyme to see what happens.
- Separate infection from inflammation. Fluctuance, systemic upset, rapid progression and discharge belong on a different pathway from a firm, tender swelling present for two weeks. If you cannot tell them apart, refer.
- Set expectations on timing. These reactions often take weeks to settle and can return with the next systemic trigger. A patient who expects resolution within days will read a normal course as a second failure.
- Record product, batch and site every time. Another clinician may need it years from now.
Most injectable training is built around the appointment itself. When you compare courses, ask what they teach about the patient who returns months later with a swelling and no records. Ask too whether you will assess such cases under an experienced clinician's supervision.
Read next
- Aseptic Technique: The Part of Injecting Nobody Photographs
- Medical History Before Injecting: What Changes the Plan
- Hyaluronidase: using it in an occlusion, and when not to